Blume-Jensen Peter 4

What Happened
Peter Blume-Jensen, President, CEO and a director of Acrivon Therapeutics (ACRV), was granted two derivative equity awards on March 1, 2026: 417,210 and 185,495 shares (total 602,705). The awards were reported at $0.00 per share in the Form 4 and are described in the filing as options that vest over time.

Key Details

• Transaction date: March 1, 2026; Form 4 filed March 3, 2026 (timely filing).
• Awards: 417,210 shares and 185,495 shares (total 602,705) reported as derivative awards at $0.00.
• Vesting: 25% of the option vests on March 1, 2027, with the remaining shares vesting in 36 substantially equal monthly installments thereafter, contingent on continuous service (footnote F1).
• Shares owned after the transaction: not specified in the provided filing.
• Spousal disclosures: Footnotes note holdings involve Dr. Kristina Masson (co‑founder/EVP) and each spouse disclaims beneficial ownership of the other's securities except to the extent of pecuniary interest (footnotes F2, F3).
• Transaction code: A = Grant/Award (derivative instrument). No 10b5‑1 plan, tax‑withholding sale, or late filing is indicated.

Context
These are time‑vesting derivative awards (options) rather than an open‑market purchase or sale. For retail investors, awards to insiders are common for compensation and retention; they increase potential insider exposure over time but do not represent an immediate cash outlay or share sale.